Spots Global Cancer Trial Database for Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)
Official Title: A Phase II Clinical Trial of Induction Chemotherapy Regimen Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) Followed by a Single Cycle of High Dose Chemotherapy (HDC) and Autologous Hematopoietic Stem Cell Rescue (AuHSCR) for Patients With Recurrent or Progressive Intracranial Germ Cell Tumors
Study ID: NCT01270724
Conditions
Interventions
Study Description
Brief Summary: This study will look to see how well patients with relapsed or recurrent intracranial germ cell tumors respond to the new combination of chemotherapy (in induction)of Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) followed by consolidation chemotherapy and autologous stem cell rescue.
Detailed Description:
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Phoenix Children's Hospital, Phoenix, Arizona, United States
Children's Hospital Los Angeles, Los Angeles, California, United States
New York University Langone Medical Center, New York, New York, United States
Nationwide Children's Hospital, Columbus, Ohio, United States
The Ohio State University Wexner Medical Center_The James Comprehensive Cancer Center, Columbus, Ohio, United States
Contact Details
Name: Randal Olshefski, MD
Affiliation: Nationwide Children's Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
